Sarcoidosis Drug Market 2021 – Research Scope, Regional Insights, Company Profile and Recent Develop pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc.
May 15, 2021 GMT
TORONTO (BUSINESS WIRE) May 15, 2021
Morganti & Co., A pro-investor law firm with licensed and experienced lawyers in Canada and the United States that represent investors announces the filing of a securities class action on behalf of investors who purchased or otherwise acquired common stock of Bellus Health, Inc. (“Bellus” or “Company”)
(NASDAQ: BLU, TSX: BLU, FWB: BHN0) from September 5, 2019 through July 5, 2020, inclusive (the “Class Period”).
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Bellus Health, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Bellus Health, Inc. securities between September 5, 2019 and July 5, 2020, inclusive . Investors have until May 17, 2021 to apply to the Court to be appointed as … Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Bellus Health, Inc. (NASDAQ: BLU) securities between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”). Investors have u
NEW YORK, May 13, 2021 /PRNewswire/ Â Pomerantz LLP is investigating claims on behalf of investors of
 BELLUS Health Inc. ( BELLUS or the Company ) (NASDAQ: BLU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether BELLUS Lidar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.Â
- Advertisement -
On July 6, 2020, Bellus provided investors with an update regarding its product BLU-5937 , in development as a treatment for chronic cough. Bellus announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked.  Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed.Â
Share this article
Share this article
NEW YORK, May 13, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of
BELLUS Health Inc. ( BELLUS or the Company ) (NASDAQ: BLU). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether BELLUS Lidar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On July 6, 2020, Bellus provided investors with an update regarding its product BLU-5937 , in development as a treatment for chronic cough. Bellus announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked. Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed.